CN104959120A - Inflammatory factor adsorbing agent for blood perfusion and preparation method - Google Patents
Inflammatory factor adsorbing agent for blood perfusion and preparation method Download PDFInfo
- Publication number
- CN104959120A CN104959120A CN201510343163.4A CN201510343163A CN104959120A CN 104959120 A CN104959120 A CN 104959120A CN 201510343163 A CN201510343163 A CN 201510343163A CN 104959120 A CN104959120 A CN 104959120A
- Authority
- CN
- China
- Prior art keywords
- carrier
- inflammatory factor
- adsorbent
- cysteine
- adsorbing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses an inflammatory factor adsorbing agent for blood perfusion and a preparation method. A framework of the inflammatory factor adsorbing agent is a carrier; and the surface of the carrier is in coupling with acetylated cysteine through an amidogen connecting arm. The carrier and the aglucon of the adsorbing agent can adsorb and remove inflammatory factors. Compared with a common adsorbing agent adsorbing the inflammatory factors by a carrier only, the inflammatory factor adsorbing agent has high removing ability. By the adsorbing agent, the inflammatory factors can be adsorbed from blood selectively, and the removing rate of the inflammatory factor adsorbing agent on IL-6 and TNF-alpha is much greater than that of a common poly (styrene-co-divinyl benzene) adsorbing agent. The adsorbing agent has high blood compatibility and can be used for whole blood perfusion.
Description
Technical field
The present invention relates to high-molecular biologic medical material, be specifically related to a kind of inflammatory factor adsorbent for blood perfusion and technology of preparing.
Background technology
Inflammatory cytokine is the general name of one group of polypeptide class Cell regulate material, comprises interleukins, interferon, growth factor, LSF, TNF etc.The illness of a lot of disease is presented in blood flow the inflammatory factor that there is high concentration.Inflammatory factor contributes to stimulation and immunity moderation system infects to help body resistance, if but overproduction in body, will autoimmune disease be produced.
The phenomenon that in body fluid, multiple inflammatory factor produces rapidly in a large number as TNF-α, IL-1, IL-6, IL-12, IFN-α, IFN-β, IFN-γ, MCP-1 and IL-8 etc. is caused after inflammatory factor storm (cytokine storm) refers to organism infection microorganism.In fact inflammatory factor storm can cause or aggravate disease, and it is also the major reason causing acute respiratory distress syndrome, MOF and life-threatening pyemia, serious burn, wound, pancreatitis, injury of lungs etc.
Albumen or the glycoprotein of most inflammatory factors to be molecular weight be 15kDa ~ 51kDa.Wherein with TNF-α, IL-6 for inflammatory factor main representative thing.TNF-α and IL-6 is otherwise known as Pro-inflammatory mediator, is the key cytokines starting antibacterial inflammatory reaction.As tripolymer, the molecular weight of TNF-α is 51kDa, there is extensive BA, secreted by the mononuclear macrophage activated, participate in immunological regulation and the inflammatory reaction of body, also be the paathogenic factor of some infectious diseases, except to except cancer cell, it has toxicity to multiple biological cell.The glycoprotein of IL-6 to be a kind of molecular weight be 21 ~ 26kDa, its cell cultured supernatant secretion acute phase protein.
Because the molecular weight of main inflammatory factor is comparatively large, and the haemodialysis of routine and peritoneal dialysis are mainly used in removing Small molecular poisonous substance, remove the limited in one's ability of inflammatory factor.At present, often utilize blood perfusion namely to adopt adsorbent to purge away the poison in one's blood and morbid substance clinically, thus reach and purify the blood, alleviate, the object of disease therapy.
The Cytosorb adsorbent (patent No. US7875182) of the U.S. effectively can remove inflammatory factor with the coated polystyrene resin of hydrophilic polymer.In addition, the domestic report having clinical practice continuous blood purification method, but its effect removing inflammatory factor is general.
Existing adsorbent uses polystyrene divinylbenzene mostly, and its blood compatibility is poor, needs to carry out coating process to adsorbent, and conventional coated fertilizer has the hydrophilic material such as collodion, polyvinyl alcohol.But there is the potential eutrophication that human body is caused that comes off of coated fertilizer.
Therefore, need to develop safer, effective inflammatory factor adsorbent.
Summary of the invention
The object of the present invention is to provide a kind of inflammatory factor adsorbent and preparation method thereof.
The technical solution used in the present invention is:
A kind of inflammatory factor adsorbent, its skeleton is carrier, and carrier surface has acetylizad cysteine by the coupling of amido linking arm.
Further, carrier is at least one in polystyrene-divinylbenzene, polymethacrylates, cellulose microsphere, agarose microbeads.
Further, the aperture of carrier is 5 ~ 50nm, and specific area is not less than 500m
2/ g.
Further, before introducing amido linking arm, as required epoxidation modification is carried out to carrier.
Further, carrier introduces amido linking arm by carrying out aminating reaction with polyamine compounds; Described polyamine compounds is at least one in hexamethylene diamine, ethylenediamine.
Further, carrying out acetylizad acylating agent to cysteine aglucon is at least one in acetic acid, chloroacetic chloride.
A kind of hemoperfusion apparatus, its adsorbent used is described above.
A kind of inflammatory factor adsorption column, its adsorbent used is described above.
A preparation method for inflammatory factor adsorbent, comprises the following steps:
1) carrier and polyamine compounds are carried out aminating reaction and introduce amido linking arm; Wherein, before aminating reaction, as required epoxidation modification is carried out to carrier;
2) carrier adding amido linking arm is mixed with cysteine solution, regulate pH to be 4 ~ 6, add amidation catalyst, make cysteine condensation be coupled on carrier;
3) add acylating agent and inflammatory factor adsorbent is prepared to the further acetylation of cysteine aglucon.
As the further improvement of above-mentioned preparation method, the catalyst of amidation process is N-hydroxy-succinamide and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride.
The invention has the beneficial effects as follows:
Inflammatory factor adsorbent of the present invention, by condensation cysteine, can change disulfide bond between inflammatory factor and inner, weaken its protein structure and make it extend, and strengthen adsorbent and be in contact with it area, thus inflammatory factor ability is removed in raising.By to the acetylation of cysteine aglucon, not only increase hydrophily, and increase the amido link of aglucon, utilize the similar principle mixed, effectively can improve the identification combination power of itself and inflammatory factor, improve the ability of its selective absorption inflammatory factor.Inflammation and allergy can make the sulfydryl enzyme of courage phosphide enzyme etc. reduce, and the sulfydryl on aglucon cysteine can maintain the activity of sulfydryl enzyme, thus can improve inflammation and irritated skin symptom.
Inflammatory factor adsorbent of the present invention has good hydrophily, can use without the need to coating process, avoids the potential eutrophication caused human body that comes off of coated fertilizer.
The carrier of adsorbent of the present invention and aglucon all have adsorption removal ability to inflammatory factor, only have higher Scavenging activity by the adsorbent of carrier adsorption than general.
Inflammatory factor adsorbent of the present invention is improved largely than common polystyrene divinylbenzene adsorbent for the clearance rate of IL-6 and TNF-α.
Other Small molecular that adsorbent of the present invention can exist from blood and hydrophilic molecule optionally adsorb inflammatory factor, and main inflammatory factor is many at below 51kDa (molecular weight as TNF-α, IL-1, IL-2, IL-6, IL-8 and IL-10 is about 51kDa, 17kDa, 15.4kDa, 26kDa, 8kDa and 18.7 kDa respectively), it is to the molecular dimension of the adsorption selection scope about 15 ~ 51kDa of inflammatory factor absorption.
Adsorbent of the present invention has good blood compatibility, has the prospect that can be applicable to whole blood perfusion.
Detailed description of the invention
As is well known to the skilled person, the carrier being applied to blood perfusion should be stable in properties, harmless to human non-toxic, does not substantially react with the material in blood simultaneously.These carriers mainly contain polystyrene divinylbenzene, polymethacrylates, cellulose microsphere, agarose microbeads etc.Wherein polystyrene divinylbenzene is hydrophobic carrier, and polymethacrylates, cellulose microsphere, agarose microbeads are hydrophilic carriers.Can, according to the design feature of carrier, utilize the residual double bonds on carrier to carry out epoxidation modification, or react with epoxychloropropane etc. and carry out epoxidation modification, be conducive to amination and introduce cysteine aglucon.
Amido linking arm is introduced further by carrying out aminating reaction with polyamine compounds; The carrier adding amido linking arm is mixed with cysteine solution, regulates pH to be 4 ~ 6, add amidation catalyst, make cysteine condensation be coupled on carrier; Its reaction condition and catalyst can be disclosed in prior art, especially, can in pH4 ~ 6, use the carrying out of NHS and EDC catalytic reaction in a mild condition.Inflammatory factor adsorbent is prepared to the further acetylation of carrier.
Below in conjunction with embodiment, further illustrate technical scheme of the present invention.
embodiment 1:
polymethyl methacrylate adsorbent
1-1 aminating reaction
(aperture 5 ~ 50nm, specific area is greater than 500m to get polymethyl methacrylate (PMMA) resin microsphere
2/ g) 10g adds the dichloroethanes soaked overnight of 10mL, then adds the dimethyl formamide solution of 10mL 50% hexamethylene diamine, stirring reaction 10 hours in 130 DEG C, rotating speed 200rpm.React rear to resin microsphere use alcohol, purified water cleaning respectively.
1-2 and cysteine condensation reaction
Get the resin microsphere that 1-1 obtains, add the cysteine solution of 20mL 1%, pH is regulated to be 4.8, add 0.8g NHS (N-hydroxy-succinamide), slowly add 0.4g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) again, in 25 DEG C, shake reaction 4 hours.React rear to clean by alcohol, purified water respectively resin.
1-3 acetylization reaction
Get the resin that 1-2 obtains, add the acetic acid solution of 20mL 0.8%, regulate pH to be 4.8, more slowly add 0.4g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC), in 25 DEG C, shake reaction 4 hours.React rear to clean by alcohol, purified water respectively resin.Prepare adsorbent, be designated as C1.
embodiment 2:
polystyrene divinylbenzene resin sorbent
The pretreatment of 2-1 epoxidation
Get polystyrene divinylbenzene resin microsphere 10g(aperture 5 ~ 50nm, specific area is not less than 500m
2/ g, cross-linker divinylbenzene purity 80%) add the dichloroethanes soaked overnight of 40mL, dropwise add the acetone soln of 20mL 1% metachloroperbenzoic acid, (temperature controls at 2 DEG C) stirring reaction 24 hours in ice-water bath, rotating speed 200rpm.React rear to clean by alcohol, purified water respectively resin microsphere.
2-2 aminating reaction
Get 2-1 resin, add the hexamethylene diamine aqueous solution of 30mL2%, in 60 DEG C, shake reaction 24 hours.React rear to clean by alcohol, purified water respectively resin microsphere.
2-3 and cysteine condensation reaction
Get the resin that 2-2 obtains, add the cysteine solution of 20mL 1.2%, pH is regulated to be 4.8, add 0.5g NHS (N-hydroxy-succinamide), slowly add 0.4g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) again, in 25 DEG C, shake reaction 5 hours.React rear to clean by alcohol, purified water respectively resin microsphere.Obtain adsorbent, be designated as C2-1.
2-4 acetylization reaction
Get the resin that 2-3 obtains, add the acetic acid solution of 20mL 0.6%, regulate pH to be 4.8, more slowly add 0.5g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC), in 30 DEG C, shake reaction 4 hours.React rear to clean by alcohol, purified water respectively resin microsphere.Obtain adsorbent, be designated as C2-2.
embodiment 3:
the agent of cellulose microsphere carrier adsorption
Get 10mL cellulose microsphere, add the epoxychloropropane of 20mL5%, in 40 DEG C, shake reaction 4 hours.Add the ethylenediamine solution of 30mL2% after cleaning, in 60 DEG C, shake reaction 24 hours.React rear to clean by alcohol, purified water respectively cellulose microsphere.Then, add the cysteine solution of 20mL 1.2%, regulate pH to be 4.8, add 0.5g NHS (N-hydroxy-succinamide), slowly add 0.4g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) again, in 25 DEG C, shake reaction 5 hours.React rear to clean by alcohol, purified water respectively cellulose microsphere.After drying, the dropping chloroacetic chloride of 20mL 6% and the dimethyl formamide solution of triethylamine shake reaction 2 hours in 30 DEG C.React rear to clean by alcohol, purified water respectively cellulose microsphere.Obtain inflammatory factor adsorbent.
embodiment 4:
the agent of agarose microbeads carrier adsorption
Get 10mL agarose microbeads, add the epoxychloropropane of 20mL5%, in 40 DEG C, shake reaction 4 hours.Add the hexamethylene diamine aqueous solution of 30mL2% after cleaning, in 60 DEG C, shake reaction 24 hours.React rear to clean by alcohol, purified water respectively agarose microbeads.Then, add the cysteine solution of 20mL 1.2%, regulate pH to be 4.8, add 0.5g NHS (N-hydroxy-succinamide), slowly add 0.4g 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDC) again, in 25 DEG C, shake reaction 5 hours.React rear to clean by alcohol, purified water respectively agarose microbeads.After drying, the dropping chloroacetic chloride of 20mL 6% and the dimethyl formamide solution of triethylamine shake reaction 2 hours in 30 DEG C.React rear to clean by alcohol, purified water respectively agarose microbeads.Obtain inflammatory factor adsorbent.
inflammatory factor adsorption experiment
Get apyrogeneity test tube, add above-mentioned obtained adsorbent and polystyrene divinylbenzene adsorbing agent carrier 0.25mL respectively, add containing inflammatory factor interleukin-6 (IL-6) 148.0pg/mL again, the blood plasma 1.5mL of TNF (TNF-α) 342.0 pg/mL, concussion absorption 2 hours (temperature 37 DEG C, concussion speed 100 ± 10rpm), then detect IL-6, TNF-α concentration, and calculate adsorbent to its clearance rate.
Absorption result is in table 1:
As shown in Table 1, the embodiment 1 adsorbent C1 that utilizes plexiglass microballoon to prepare reaches 75% ~ 81% for the clearance rate of inflammatory factor.The clearance rate of simple use polystyrene divinylbenzene adsorbent to inflammatory factor is about 40%, and p-poly-phenyl ethene divinylbenzene resin microballoon is through immobilized cysteine (adsorbent C2-1) in embodiment 2, it can be greatly enhanced to more than 60% to the Scavenging activity of inflammatory factor.And after acetylation (adsorbent C2-2), its clearance rate can reach more than 80%.
hemolytic experiment
Get its hemolysis rate of absorbent measuring (wherein hemolytic test is according to GB/T16886.4-2003 " BiologicalEvaluationofMedicalDevice the 4th part and blood interact to test and selects ", GB/T16175-2008 " medical organic silicon material biological assessment test method ").
Sample thief group often pipe adds test sample 5g, then adds sodium chloride injection 10ml; Negative control group often pipe adds sodium chloride injection 10ml; Positive controls often pipe adds distilled water 10ml.Often organize operation repetitive 3 to manage.After water bath with thermostatic control (37 ± 1) DEG C insulation 30min put into by whole test tube, often prop up test tube and add 0.2ml dilution rabbit blood, mix gently, put (37 ± 1) DEG C warm 60 min of water-bath relaying continuation of insurance.Pour out liquid in pipe with centrifugal 5 min of 800g.Aspirate supernatant moves in cuvette, measures absorbance with spectrophotometer at 545nm wavelength place.Sample combination control group absorbance all gets the mean value of 3 pipes.The absorbance of negative control pipe should be not more than 0.03, and the absorbance of positive control pipe should be 0.8 ± 0.3, otherwise should again test.
Experimental result: obtain the hemolysis rate that adsorbent comprises adsorbent C1, C2-1, C2-2 and be less than 1%, comply with the national standard requirements lower than 5%.
blood compatibility is tested
Get adsorbent (comprising adsorbent C1, C2-1, C2-2) each 1mL, load after physiological saline soaks 10 hours in perfusion device, inject 10mL through the rabbit whole blood of liquaemin anti-freezing with syringe, with the flow velocity perfusion 2 hours of 50mL/min, add an empty perfusion device simultaneously and carry out control experiment.The change of each component of blood before and after perfusion is measured through Beckman LH750 cellanalyzer.
Result shows, before and after perfusion, in blood, the change of the key component such as red blood cell is little, and the percentage of decline, all within 8%, shows that this serial adsorbent has good blood compatibility thus, has the prospect that can be applicable to whole blood perfusion.
Claims (10)
1. an inflammatory factor adsorbent, its skeleton is carrier, and carrier surface has acetylizad cysteine by the coupling of amido linking arm.
2. a kind of inflammatory factor adsorbent according to claim 1, is characterized in that: carrier is at least one in polystyrene-divinylbenzene, polymethacrylates, cellulose microsphere, agarose microbeads.
3. a kind of inflammatory factor adsorbent according to claim 1 and 2, is characterized in that: the aperture of carrier is 5 ~ 50nm, and specific area is not less than 500m
2/ g.
4. a kind of inflammatory factor adsorbent according to claim 1 and 2, is characterized in that: before introducing amido linking arm, carry out epoxidation modification as required to carrier.
5. a kind of inflammatory factor adsorbent according to claim 1, is characterized in that: carrier introduces amido linking arm by carrying out aminating reaction with polyamine compounds; Described polyamine compounds is at least one in hexamethylene diamine, ethylenediamine.
6. a kind of inflammatory factor adsorbent according to claim 1, is characterized in that: carrying out acetylizad acylating agent to cysteine aglucon is at least one in acetic acid, chloroacetic chloride.
7. a hemoperfusion apparatus, is characterized in that: its adsorbent used is as described in claim 1 ~ 6 any one.
8. an inflammatory factor adsorption column, is characterized in that: its adsorbent used is as described in claim 1 ~ 6 any one.
9. a preparation method for inflammatory factor adsorbent, comprises the following steps:
Carrier and polyamine compounds are carried out aminating reaction and introduces amido linking arm; Wherein, before aminating reaction, as required epoxidation modification is carried out to carrier;
The carrier adding amido linking arm is mixed with cysteine solution, regulates pH to be 4 ~ 6, add amidation catalyst, make cysteine condensation be coupled on carrier;
Add acylating agent and inflammatory factor adsorbent is prepared to the further acetylation of cysteine aglucon.
10. preparation method according to claim 9, is characterized in that: the catalyst of amidation process is N-hydroxy-succinamide and 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510343163.4A CN104959120B (en) | 2015-06-19 | 2015-06-19 | Inflammatory factor adsorbing agent for blood perfusion and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510343163.4A CN104959120B (en) | 2015-06-19 | 2015-06-19 | Inflammatory factor adsorbing agent for blood perfusion and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104959120A true CN104959120A (en) | 2015-10-07 |
| CN104959120B CN104959120B (en) | 2017-05-10 |
Family
ID=54213304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510343163.4A Active CN104959120B (en) | 2015-06-19 | 2015-06-19 | Inflammatory factor adsorbing agent for blood perfusion and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104959120B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108311121A (en) * | 2018-01-25 | 2018-07-24 | 珠海健帆生物科技股份有限公司 | A kind of blood perfusion absorption resin and preparation method thereof and perfusion device |
| CN108855003A (en) * | 2018-06-28 | 2018-11-23 | 南开大学 | It is a kind of for removing the immunosorbent and preparation method thereof of inflammatory factor in blood |
| CN109562219A (en) * | 2016-09-09 | 2019-04-02 | 东丽株式会社 | For purifying the material of blood |
| CN109843347A (en) * | 2016-11-29 | 2019-06-04 | 富士胶片株式会社 | Blood constituent selects absorption filtering material and blood filter |
| CN111632202A (en) * | 2020-06-29 | 2020-09-08 | 南开大学 | Tumor cell adhesion material and preparation method and application thereof |
| CN115845822A (en) * | 2023-02-27 | 2023-03-28 | 佛山市博新生物科技有限公司 | Adsorbing material for removing blood cell factor and preparation method thereof |
| CN116586048A (en) * | 2023-07-17 | 2023-08-15 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476908A (en) * | 2003-07-15 | 2004-02-25 | 南开大学 | Spherical amino acid adsorbent and its preparation method |
| CN1665494A (en) * | 2002-07-08 | 2005-09-07 | 甘布罗伦迪亚股份有限公司 | Polymer affinity matrix, a method for the production and use thereof |
| CN103230781A (en) * | 2013-05-03 | 2013-08-07 | 重庆大学 | Heparin-phenylalanine adsorption material for blood purification method for removing endotoxin |
| US20140369937A1 (en) * | 2011-06-11 | 2014-12-18 | University Of Central Florida Research Foundation, Inc. | Activatable nanoprobes for intracellular drug delivery |
| CN104525151A (en) * | 2014-12-02 | 2015-04-22 | 佛山市博新生物科技有限公司 | Endotoxin adsorbent used in hemoperfusion, and preparation method thereof |
-
2015
- 2015-06-19 CN CN201510343163.4A patent/CN104959120B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1665494A (en) * | 2002-07-08 | 2005-09-07 | 甘布罗伦迪亚股份有限公司 | Polymer affinity matrix, a method for the production and use thereof |
| CN1476908A (en) * | 2003-07-15 | 2004-02-25 | 南开大学 | Spherical amino acid adsorbent and its preparation method |
| US20140369937A1 (en) * | 2011-06-11 | 2014-12-18 | University Of Central Florida Research Foundation, Inc. | Activatable nanoprobes for intracellular drug delivery |
| CN103230781A (en) * | 2013-05-03 | 2013-08-07 | 重庆大学 | Heparin-phenylalanine adsorption material for blood purification method for removing endotoxin |
| CN104525151A (en) * | 2014-12-02 | 2015-04-22 | 佛山市博新生物科技有限公司 | Endotoxin adsorbent used in hemoperfusion, and preparation method thereof |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562219A (en) * | 2016-09-09 | 2019-04-02 | 东丽株式会社 | For purifying the material of blood |
| CN109562219B (en) * | 2016-09-09 | 2021-05-18 | 东丽株式会社 | Material for purifying blood |
| CN109843347A (en) * | 2016-11-29 | 2019-06-04 | 富士胶片株式会社 | Blood constituent selects absorption filtering material and blood filter |
| CN108311121A (en) * | 2018-01-25 | 2018-07-24 | 珠海健帆生物科技股份有限公司 | A kind of blood perfusion absorption resin and preparation method thereof and perfusion device |
| CN108311121B (en) * | 2018-01-25 | 2021-05-14 | 健帆生物科技集团股份有限公司 | Adsorption resin for blood perfusion, preparation method thereof and perfusion apparatus |
| CN108855003A (en) * | 2018-06-28 | 2018-11-23 | 南开大学 | It is a kind of for removing the immunosorbent and preparation method thereof of inflammatory factor in blood |
| CN108855003B (en) * | 2018-06-28 | 2021-01-05 | 南开大学 | Immunoadsorbent for removing inflammatory factors in blood and preparation method thereof |
| CN111632202A (en) * | 2020-06-29 | 2020-09-08 | 南开大学 | Tumor cell adhesion material and preparation method and application thereof |
| CN115845822A (en) * | 2023-02-27 | 2023-03-28 | 佛山市博新生物科技有限公司 | Adsorbing material for removing blood cell factor and preparation method thereof |
| CN116586048A (en) * | 2023-07-17 | 2023-08-15 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
| CN116586048B (en) * | 2023-07-17 | 2023-09-08 | 江苏恰瑞生物科技有限公司 | Modified polystyrene adsorption resin for blood perfusion device and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104959120B (en) | 2017-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104959120B (en) | Inflammatory factor adsorbing agent for blood perfusion and preparation method | |
| US7279106B2 (en) | Adsorbent and method for adsorbing a chemokine in body fluid | |
| JP6031069B2 (en) | Apparatus and method for restoring blood pathology | |
| US5403917A (en) | Process for the quantitative selective removal or preparative isolation of tumour necrosis factor (TNF) or/and lipopolysaccharides (LPS) from aqueous liquids | |
| US20140131276A1 (en) | Device and method for restoration of the condition of blood | |
| CN104525151A (en) | Endotoxin adsorbent used in hemoperfusion, and preparation method thereof | |
| EP1191034B1 (en) | Enterotoxin adsorbent, method of adsorptive removal, and adsorption apparatus | |
| CN105664868A (en) | Endotoxin adsorption material for blood purification and preparation method and application of endotoxin adsorption material for blood purification | |
| JP2001218840A (en) | Adsorbent for transforming growth factor. beta, adsorbing/removing method, and adsorber | |
| CN108855003B (en) | Immunoadsorbent for removing inflammatory factors in blood and preparation method thereof | |
| CN107199024B (en) | Adsorbent for removing low-density lipoprotein in blood and preparation method thereof | |
| CN105032358A (en) | Amphipathic low-density lipoprotein adsorbent and preparation method thereof | |
| CA2216718C (en) | Adsorbent for disease-related factors in body fluids, method of elimination by adsorption, body fluid purifier, and apparatus for purifying body fluids | |
| CN103230781A (en) | Heparin-phenylalanine adsorption material for blood purification method for removing endotoxin | |
| CA1283073C (en) | Adsorbent for purification of blood coagulation factor viii and process for purification of blood coagulation factor viii using the same | |
| JPS59169532A (en) | Adsorbing material of c-reactive protein | |
| CN1583245A (en) | Endotoxin adsorptive material, preparing and use thereof | |
| JPH0245064A (en) | Device for removing interleukin 2 receptor and blood extra-corporeal circulating device provided with this device | |
| CN112755973B (en) | Composite adsorption material applied to blood purification field and preparation method thereof | |
| JP3157026B2 (en) | Adsorbent for blood purification | |
| CN114950383B (en) | Cytokine adsorbent for blood purification and preparation method thereof | |
| JP5250288B2 (en) | Method for operating body fluid purification system | |
| JPH0771632B2 (en) | Adsorbent and removal device using the same | |
| CN116618024A (en) | Blood purifying adsorbent and preparation method thereof | |
| JPH0431735B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |